Please assess the completion status of the following clinical trial:

Trial Title: Anidulafungin In Treatment Of Candidemia In Asian Subjects

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with at least one positive blood test for Candida pathogen from a blood sample taken within 96 hours prior to start of study treatment.~* Subjects with clinical evidence of candida infection within 48 hours prior to enrollment.~* Acute Physiology and Chronic Health Enquiry (APACHE) score less than or equal to 20.~Exclusion Criteria:~* Prior exposure to systemic antifungals for more than 48 hours.~* Subjects who had, at any time, previously received anidulafungin.~* Subjects with poor venous (vein) access that would inhibit the administration of the intravenous study drug or withdrawing of multiple blood samples.~* Life expectancy \< 72 hours.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open (Type: OTHER): This is an open-label, multi-center, non-comparative 12 week study evaluating the efficacy and safety of anidulafungin in subjects with candidemia.

Based on this trial design, predict the completion outcome and termination type (if applicable).